Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: Retrospective assessment in 1470 patients

Blood

Volumn 123, Issue 24, 2014, Pages 3803-3810

  Geyer, Holly L ^a   Scherber, Robyn M ^a   Dueck, Amylou C ^a   Kiladjian, Jean Jacques ^b   Xiao, Zhijian ^c   Slot, Stefanie ^d   Zweegman, Sonja ^d   Sackmann, Federico ^e   Fuentes, Ana Kerguelen ^f   Hernández Maraver, Dolores ^f   Döhner, Konstanze ^g   Harrison, Claire N ^h   Radia, Deepti ^h   Muxi, Pablo ⁱ   Besses, Carlos ^j   Cervantes, Francisco ^k   Johansson, Peter L ^l   Andreasson, Bjorn ^l   Rambaldi, Alessandro ^m   Barbui, Tiziano ^m   Vannucchi, Alessandro M ⁿ   Passamonti, Francesco ^o   Samuelsson, Jan ^p   Birgegard, Gunnar ^q   Mesa, Ruben A ^a   more..

^a MAYO CLINIC   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Fundacion para Combatir La Leucemia   (Argentina)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ British Hospital Montevideo   (Uruguay)

^j HOSPITAL DEL MAR   (Spain)

^k UNIVERSITY OF BARCELONA   (Spain)

^l Nephro Urology Hospital Organization   (Sweden)

^m Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

ⁿ OSPEDALE DI CIRCOLO   (Italy)

^o UNIVERSITY OF PAVIA   (Italy)

^p STOCKHOLM SÖDER HOSPITAL   (Sweden)

^q UPPSALA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BLEEDING; BONE PAIN; CLUSTER ANALYSIS; COUGHING; DIZZINESS; FATIGUE; FEMALE; FEVER; GENDER; HEADACHE; HUMAN; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOOD CHANGE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NIGHT SWEAT; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SPLEEN SIZE; SYMPTOM; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW NEOPLASMS; CLUSTER ANALYSIS; FEMALE; GEOGRAPHY; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84902595006     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-527903     Document Type: Article

References (27)

1. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76. (Pubitemid 46120195)
2. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199-1203.
3. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401-408.
4. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098-4103.
5. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186-1196. (Pubitemid 29115600)
6. Abelsson J, Andréasson B, Samuelsson J, et al. Patients with polycythemia vera have the worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma. 2013;54(10):2226-2230.
7. Wild D, Grove A, Martin M, et al; ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005;8(2):94-104. (Pubitemid 40525371)
8. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857-2858.
9. Tefferi A, Rumi E, Finazzi G, et al. Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. Blood. 2012;118(21):277a.
10. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197-1201.
11. Hall SA, Cinar A, Link CL, et al. Do urological symptoms cluster among women? Results from the Boston Area Community Health Survey. BJU Int. 2008;101(10):1257-1266. (Pubitemid 351549639)
12. Cinar A, Hall SA, Link CL, et al. Cluster analysis and lower urinary tract symptoms in men: findings from the Boston Area Community Health Survey. BJU Int. 2008;101(10):1247-1256. (Pubitemid 351549637)
13. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476.
14. Khan SN, Jankowska AM, Mahfouz R, et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia. 2013;27(6):1301-1309.
15. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23(11):2183-2186.
16. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24(7):1302-1309.
17. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
18. Sanada M, Suzuki T, Shih LY, et al. Gain-offunction of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257):904-908.
19. Jäger R, Gisslinger H, Passamonti F, et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia. 2010;24(7):1290-1298.
20. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2012;26(3):475-480.
21. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
22. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
23. Verstovsek S, Passamoni F, Rambaldi A, et al. Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). Blood. 2010;116(suppl):abstr313.
24. Pardanani A, Geeta G, Lasho TL, et al. A Phase I/II study of CYT387, an oral JAK-1/2 Inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood. 2010;116(suppl):abstr 460.
25. Deeg H, Odenike O, Scott B, et al. Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis. J Clin Oncol. 2011;29(suppl):abstr 6515.
26. Pardanani AD, Gotlib J, Jamieson C, et al. A phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. Blood. 2009;114(suppl): abstr 755.
27. Shabbir M, Stuart R. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs. 2010;19(3):427-436.